FDA Signals Single Trial May Be Enough for BioCardia's CardiAMP Heart Failure Therapy PMA
BCDA sits 63% above its 52-week low of $0.84 on light trading volume (0.3× avg).
Summary
The FDA has confirmed that BioCardia's ongoing CardiAMP HF II trial data may support a Premarket Approval (PMA) submission for its cell therapy in ischemic heart failure. This is a highly positive regulatory update, as the FDA typically prefers two trials for such a large indication, potentially accelerating the approval timeline and reducing costly development. This news offers a critical path forward for BioCardia, which has been grappling with severe liquidity issues, a cash runway only until June 2026, and Nasdaq delisting risk, as detailed in recent SEC filings. The company plans to complete the US trial for PMA.
At the time of this announcement, BCDA was trading at $1.37 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $10.5M. The 52-week trading range was $0.84 to $2.45. This news item was assessed with positive market sentiment and an importance score of 9 out of 10. Source: Wiseek News.